7th Conference on Retroviruses and Opportunistic Infections San Francisco, CA - January 30 -February 4, 2000

Conf Retroviruses Opportunistic Infect 2000 Jan 30-Feb 2; 7:76 (abstract no. 5)

R. F. Little¹, J. M. Pluda¹, K. Wyvill¹, J. Lietzau¹, G. Shearer¹, G. Tosato², E. Feigal¹, C. Chougnet¹, K. Fowke¹, And R. Yarchoan^1
1NCI and ²FDA, Bethesda, MD

BACKGROUND: IL-12 inhibits angiogenesis by stimulating interferon-γ (IFN-γ) production with subsequent induction of inducible protein-10 (IP-10). IL-12 also modulates TH1 cell development, restores HIV-specific T-cell immune responses, and enhances cytotoxic and natural killer T-cells.

METHODS: Eligible pts took stable antiviral therapy for > 4 wks prior to entry; had no visceral KS or active opportunistic infections; and received no KS therapy within 3 wks of entry. Successive cohorts received escalating doses (ng/kg) of 100 (5 pts), 300 (6 pts), and 500 (5 pts) administered subcutaneously twice weekly.

RESULTS: The median (range) entry CD4 cell count and HIV viral load was 306/mm³ (17-602) and 1601 copies/mL (<200-157,000), respectively. 15/16 pts had ACTG staging poor risk features. 15/16 pts had received prior KS treatment. G-CSF responsive leukopenia developed in 6 pts. 2 pts withdrew for IL-12-related toxicity: 1 for reversible transaminitis and 1 for hemolytic anemia. A self-limiting flu-like syndrome occurred frequently with initial doses of IL-12. CD4 cells counts and viral load were stable during treatment. No responses were seen in the 4 evaluable patients receiving 100 ng/kg. 5/5 and 3/5 evaluable pts receiving 300 and 500 ng/kg , respectively, achieved a partial response (80% response rate, 95% CI= 55-100%). Of these, 6 had prior KS progression on HAART. With a median follow-up of 46 weeks, no responding pts have had KS progression. Enrollment at higher doses continues.

CONCLUSION: IL-12 appears to be well tolerated in KS at current doses. Primary toxicities include reversible neutropenia, hepatotoxicity, and self-limiting constitutional symptoms. Among pts at the 300 and 500 ng/kg dose levels, an 80% long-lasting partial response rate was achieved.

2000-01-30
5

Copyright © 2000 - Foundation for Retrovirology and Human Health (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the Foundation for Retrovirology and Human Health. Licensed from National Library of Medicine.